Compound
(-)-epigallocatechin 3-gallate
A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (−)-epigallocatechin.
Definition from ChEBI (CHEBI:4806), read 2026-09-23. CC BY 4.0.
Studied for
16 endpoints · 20 findings · 14 papers · 1 null
- Maximal oxygen uptakeraisesEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.
- Body masslowersEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
- LDL cholesterollowersEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
- BrainraisesEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
- DYRK1AlowersEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
Structure
A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (−)-epigallocatechin.
Loading the model…
- Class
- Organic compound
- Formula
- C22H18O11
- Mass
- 458.375 g/mol
- Charge
- 0
- InChIKey
- WMBWREPUVVBILR-WIYYLYMNSA-N
- SMILES
- O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence.
What the evidence says
How to read these marks20 findings · 16 endpoints · 14 papers · 1 null · by evidence strength
- Evidence strength
- Strong
- Moderate
- Limited
- Very limited
- Insufficient
| Endpoint | Lowered11 findings, 7 endpoints | No detected effect1 finding, 1 endpoint | Raised2 findings, 2 endpoints | Other6 findings, 6 endpoints |
|---|---|---|---|---|
| Maximal oxygen uptake | ||||
| Body mass | ||||
| LDL cholesterol | ||||
| Accumulates in brain | ||||
| Fasting blood glucose | ||||
| Glycated haemoglobin (HbA1c) | ||||
| HOMA-IR | ||||
| Inhibits DYRK1A | ||||
| Interleukin-6 concentration | ||||
| Serum adiponectin | ||||
| Tumour necrosis factor alpha concentration | ||||
| Inhibits EGFR | ||||
| Inhibits EPHB2 | ||||
| Inhibits SLCO1A2 | ||||
| Inhibits STAT3 | ||||
| Measured, and no finding detected an effect | ||||
| Lean body mass | ||||
What moved
19 findings
Increases maximal oxygen uptake
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Compared with placebo, short-term EGCG consumption increased VO2max (Table 2; mean change = +0.136 ± 0.064 L·min-1; P = 0.04;).”
Quoted verbatim from Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans.. - Study
- crossover
- Duration
- 2 days
- Dose
- Teavigo EGCG 135 mg per capsule, one capsule with each meal for 48 h before testing, final capsule 2 h before exercise test
- Population
- Healthy adult males and females, randomized double-blind repeated-measures design with each participant tested on placebo and EGCG; VO2max by breath-by-breath indirect calorimetry during incremental stationary cycle ergometer exercise to volitional fatigue
Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans.2010PMID:19952844Permalink
Decreases HOMA-IR
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR.”
Quoted verbatim from Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Pooled across 41 randomized controlled trials of EGCG supplementation (meta-analysis of glycemic index and related parameters).
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40885603Permalink
Inhibits DYRK1A
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“As expected, the DYRK1A-ΔC and DYRK1A activities decreased with increasing concentrations of EGCG (Table 1 and Table 2).”
Quoted verbatim from Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.. - Study
- in vitro · not in humans
- Dose
- concentrations up to 100 uM
- Population
- Purified recombinant DYRK1A catalytic domain and native human DYRK1A, in vitro kinase assay with fluorescent peptide substrate and 1 mM ATP
Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.2020PMID:32092951Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Nevertheless, the body weight of mice belonging to the CE group was significantly lower than those belonging to the CW group, starting at the fourth week until the end of experimental treatment (p < 0.001).”
Quoted verbatim from Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.. - Study
- animal · not in humans
- Duration
- 4 months
- Dose
- green tea extract 98% EGCG, 50 mg/kg/day by gavage
- Population
- Male Swiss mice on a control diet (AIN-93), CE group (green tea extract) versus CW group (water by gavage), 16 weeks; difference from week 4 onward
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.2015PMID:26536464Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“By contrast high fat-fed mice treated with EGCG showed a 21.7% reduction in the rate of body weight gain and a 9.4% decrease in final body weight (p < 0.05, Table 1).”
Quoted verbatim from (-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice.. - Study
- animal · not in humans
- Duration
- 4 months
- Dose
- 0.32% EGCG in the diet
- Population
- High-fat-fed C57bl/6J mice given 0.32% EGCG in the diet for 16 weeks versus high-fat-fed mice without EGCG; final body weight
(-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice.2011PMID:21779555Permalink
Increases serum adiponectin
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Adiponectin presented a significantly higher level in the HFE group as compared with the HFW group (p = 0.031) and in the CE group as compared with the CW group (p = 0.046).”
Quoted verbatim from Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.. - Study
- animal · not in humans
- Duration
- 4 months
- Dose
- green tea extract 98% EGCG, 50 mg/kg/day by gavage
- Population
- Male Swiss mice after 16 weeks, 12-hour fasted; green tea extract versus water by gavage in both high-fat-diet mice (HFE vs HFW) and control-diet mice (CE vs CW)
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.2015PMID:26536464Permalink
Show the remaining 13
Decreases LDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“LDL-c level was also reduced in the HFE group as compared with the HFW group (p = 0.011).”
Quoted verbatim from Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.. - Study
- animal · not in humans
- Duration
- 4 months
- Dose
- green tea extract 98% EGCG, 50 mg/kg/day by gavage
- Population
- Male Swiss mice fed a high-fat diet for 16 weeks, green tea extract (HFE) versus water by gavage (HFW), 12-hour fasted
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.2015PMID:26536464Permalink
Decreases LDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“According to weighted mean differences for changes from baseline with 95% confidence intervals (CI), 107-856 mg/d of EGCG for 4 to 14 weeks reduced LDL-C by -9.29 mg/dl (95% CI, -12.27 to -6.31).”
Quoted verbatim from Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans.. - Study
- meta-analysis
- Dose
- 107-856 mg/d for 4 to 14 weeks
- Population
- healthy individuals, pooled across 17 randomized controlled trials of EGCG for 4 to 14 weeks
Effect -9.29 mean difference, 95% CI -12.27 to -6.31
Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans.2016PMID:27324590Permalink
Decreases fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR.”
Quoted verbatim from Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Pooled across 41 randomized controlled trials of EGCG supplementation (meta-analysis of glycemic index and related parameters).
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40885603Permalink
Decreases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“After treatment with EGCG, IL-2 and IFN-γ levels were significantly increased (P<0.05 vs. asthma group); IL-4, IL-6 and TNF-α levels were significantly diminished (P<0.05 vs. asthma group).”
Quoted verbatim from Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.. - Study
- animal · not in humans
- Duration
- 7 days
- Dose
- 10 or 20 mg/kg/day EGCG by caudal vein injection; the sentence does not say which EGCG group
- Population
- Male Balb/c mice with ovalbumin-induced asthma, serum cytokines by cytometric bead array, EGCG-treated groups versus untreated asthma model group
Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.2018PMID:29916550Permalink
Decreases interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“After treatment with EGCG, IL-2 and IFN-γ levels were significantly increased (P<0.05 vs. asthma group); IL-4, IL-6 and TNF-α levels were significantly diminished (P<0.05 vs. asthma group).”
Quoted verbatim from Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.. - Study
- animal · not in humans
- Duration
- 7 days
- Dose
- 10 or 20 mg/kg/day EGCG by caudal vein injection; the sentence does not say which EGCG group
- Population
- Male Balb/c mice with ovalbumin-induced asthma, serum cytokines by cytometric bead array, EGCG-treated groups versus untreated asthma model group
Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.2018PMID:29916550Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“EGCG-treated (fed with a 60 kcal% high-fat diet supplemented with 1% EGCG) mice showed an obvious reduction in body weight, lipid deposition, and epididymal adipocytes size.”
Quoted verbatim from Green Tea Polyphenol (-)-Epigallocatechin Gallate (EGCG) Attenuates Neuroinflammation in Palmitic Acid-Stimulated BV-2 Microglia and High-Fat Diet-Induced Obese Mice.. - Study
- animal · not in humans
- Duration
- 8 weeks
- Dose
- 1% EGCG blended into the diet for 8 weeks
- Population
- Male C57BL/6J mice with high-fat-diet-induced obesity, EGCG-supplemented high-fat diet versus high-fat diet alone
Green Tea Polyphenol (-)-Epigallocatechin Gallate (EGCG) Attenuates Neuroinflammation in Palmitic Acid-Stimulated BV-2 Microglia and High-Fat Diet-Induced Obese Mice.2019PMID:31614951Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“As indicated in Figure 1, EGCG treatment reduced body weight by 10% and gonadal WAT (gWAT) mass by 20%.”
Quoted verbatim from Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 20 mg/kg/day by oral gavage for 2 weeks
- Population
- Male C57BL/6 mice fed a high-fat diet for 8 weeks, then treated with EGCG or vehicle for 2 weeks under continued high-fat diet
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.2020PMID:33050029Permalink
Decreases glycated haemoglobin (HbA1c)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Notably, the reduction in HbA1c (WMD: -0.18%, 95% CI: -0.35, -0.02; P = 0.029) was small and may not equate to clinically meaningful benefits for all populations.”
Quoted verbatim from Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Pooled across 41 randomized controlled trials of EGCG supplementation (meta-analysis of glycemic index and related parameters).
Effect -0.18 mean difference, 95% CI -0.35 to -0.02
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40885603Permalink
Accumulates in brain
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“We first demonstrated that EGCG can be detected in plasma and brain tissue using mass spectral analysis.”
Quoted verbatim from Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.. - Study
- animal · not in humans
- Dose
- FontUp 50 mg/kg by oral gavage, morning and evening
- Population
- Male wild-type and TgBACDyrk1A mice given FontUp (EGCG-enriched supplement) by oral gavage
Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.2020PMID:32092951Permalink
Inhibits EGFR
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“EGCG also suppressed EGFR expression, especially in Hep3BLR.”
Quoted verbatim from Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.. - Study
- in vitro · not in humans
- Dose
- 10 μg/ml
- Population
- Hep3B human hepatocellular carcinoma cells and the lenvatinib-resistant Hep3BLR subline
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.2025PMID:41006034Permalink
Inhibits EPHB2
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“Western blot analysis confirmed diminished ERK activity in the EGCG-treated arteries, with a diminished phospho:total ERK ratio in the EGCG-treated arteries (P=.036, Mann-Whitney U test; Figure 4).”
Quoted verbatim from Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 1 mg/kg EGCG intraperitoneally daily from one day before surgery
- Population
- Wire-injured common carotid arteries of male Sprague-Dawley rats given daily intraperitoneal EGCG versus saline, harvested at 2 weeks
Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.2013PMID:23538007Permalink
Inhibits SLCO1A2
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“EGCG competitively inhibited OATP1A2-mediated uptake of sulphobromophthalein and nadolol with Ki values of 21.6 and 19.4 μM, respectively.”
Quoted verbatim from Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.. - Study
- in vitro · not in humans
- Population
- human embryonic kidney 293 cells stably expressing OATP1A2
Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.2018PMID:29480324Permalink
Inhibits STAT3
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“EGCG dose-dependently inhibited Stat3 activation induced by IL-6, but did not change the total Stat3 expression.”
Quoted verbatim from (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer.. - Study
- in vitro · not in humans
- Population
- Human gastric cancer (AGS) cells stimulated with IL-6 (50 ng/mL) and treated with EGCG at different concentrations
(-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer.2011PMID:21633597Permalink
What did not
1 finding
No detected effect on lean body mass
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.FindingNull result“No change was observed in lean mass by EGCG (Figure.”
Quoted verbatim from The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats.. - Study
- animal · not in humans
- Dose
- 50 mg/kg/d
- Population
- Adult male Wistar rats fed a high-fat diet (obese model); body composition assessed at 100 weeks, EGCG group vs HF group.
The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats.2020PMID:32729662Permalink
What it touches on the way
Mechanistic reach
4 entities
4 entities reached.
0 reported hops4 assembled from the scaffold
On the label
Labelled products
62 products
Source: NIH DSLD · Ingredient: (-)-epigallocatechin 3-gallate · 62 products · Declared amount per serving: 20–700 mg (61 products)
61 labels state an amount1 does not
- 21st CenturyOne Daily Weight ControlGreen Tea extract · EGCG (Form: from Green Tea extract PlantPart: leaf Genus: Camellia Species: sinensis)32 mgper 1 Tablet(s)DSLD:11560
- 8WeeksOutLipogenXGreen Tea extract400 mgper 2 Capsule(s)DSLD:228503
- 8WeeksOutOxyvar400 mgper 1 Capsule(s)DSLD:228515
- Blackstone LabsCarnitrim100 mgper 1 Tablet(s)DSLD:219533
- CymbiotikaOrganic Longevity Mushrooms Chocolate Fudge SyrupGreen Tea extract50 mgper 15 mLDSLD:253134
- D'Adamo Personalized NutritionCatalystCamilla sinensis · EGCG (Form: from standardized extract of Camilla sinensis CorrectedName: Camellia sinensis PlantPart: Leaf Genus: Camillia Species: sinensis) (Alt. Name: Epigallocatechin Gallate)25 mgper 1 Capsule(s)DSLD:27255
- DioxymeFat Loss150 mgper 1 Capsule(s)DSLD:282183
- GNC AMP Advanced Muscle PerformanceDecaf Thermo Igniter 12XGreen Tea leaf extract · EGCG (Form: from Green Tea leaf extract PlantPart: leaf) (Alt. Name: Epigallocatechin Gallate)50 mgper 1 Yellow Caplet(s)DSLD:183545
- GNC AMP Advanced Muscle PerformanceDecaf Thermo Igniter 12XGreen Tea leaf extract · EGCG (Form: from Green Tea leaf extract PlantPart: leaf) (Alt. Name: Epigallocatechin Gallate)50 mgper 1 Caplet(s)DSLD:228068
- GNC AMP Advanced Muscle PerformanceDecaf Thermo Igniter 12XGreen Tea leaf extract50 mgper 1 Yellow Caplet(s)DSLD:312711
- GNC AMP Advanced Muscle PerformanceDecaf Thermo Igniter 12XGreen Tea Leaf Extract50 mgper 1 Yellow Tablet(s)DSLD:336011
- GNC BodyDynamixDiet DetoxGreen Tea extract · EGCG (Form: as Green Tea extract) (Alt. Name: Epigallocatechin Gallate)25 mgper 1 Caplet(s)DSLD:182869
Show the remaining 50
- GNC Pro Performance AMPDecaf Thermo Igniter 12Xdecaffeinated Green Tea leaf extract · EGCG (Form: from decaffeinated Green Tea leaf extract PlantPart: leaf) (Alt. Name: Epigallocatechin Gallate)50 mgper 1 Yellow Caplet(s)DSLD:176168
- GNC SuperFoodsBeauty, Antioxidant, Stress & ImmuneGreen Tea extract · Epigallocatechin (Form: from Green Tea extract Genus: Camellia Species: sinensis) (Alt. Name: EGCG)25 mgper 1 Capsule(s)DSLD:176273
- GNC SuperFoodsUltra Mega Green Active BerryGreen Tea leaves extract · EGCG (Form: from Green Tea leaves extract PlantPart: leaves)100 mgper 37 Gram(s)DSLD:78327
- GNC Total Lean AdvancedSystem Detox & Metabolic Support BlendGreen Tea extract · EGCG (Form: from Green Tea extract (Form: standardized to 75% EGCG Note: = 18.75 mg) PlantPart: leaf Genus: Camellia Species: sinensis)25 mgper 1 Green Tablet(s)DSLD:82946
- GNC Total Lean AdvancedTone & Define Pink Lemonadedecaffeinated Green Tea extract · EGCG (Form: from decaffeinated Green Tea extract PlantPart: leaf Genus: Camellia Species: sinensis)25 mgper 6.9 Gram(s)DSLD:47950
- GT Genesis TodayNature Trim 5Green Tea extract125 mgper 3 Capsule(s)DSLD:73922
- Highland LaboratoriesBerry WellnessGreen Tea · EGCG (Form: from Green Tea PlantPart: leaf and flower Genus: Camillia Species: sinensis Note: standardized extract, and White Tea PlantPart: leaf and flower Genus: Camillia Species: sinensis Note: standardized extract) (Alt. Name: Epigallocatechin Gallate)150 mgper 1 Vegetarian Capsule(s)DSLD:3252
- Infiniti Creations100% Pure Raspberry Ketones 250 mgEGCG Green Tea extract Note: 50%100 mgper 1 Capsule(s)DSLD:238986
- Infiniti CreationsPAGG DaytimeGreen Tea extract · EGCG (Form: as Green Tea extract)405 mgper 3 Capsule(s)DSLD:238981
- Jacked FactoryLean PMGreen Tea leaf extract300 mgper 2 Capsule(s)DSLD:257767
- Jacked FactoryLean PMGreen Tea leaf extract300 mgper 2 Capsule(s)DSLD:261027
- Jacked FactoryLean PMGreen Tea leaf extract300 mgper 2 Capsule(s)DSLD:317097
- Jacked FactoryLean PMGreen Tea Leaf Extract300 mgper 2 Capsule(s)DSLD:337384
- Jacked Factory JFThermo XTGreen Tea extract300 mgper 1 Capsule(s)DSLD:292143
- Life ExtensionCytokine Supress with EGCGGreen Tea leaf extract300 mgper 1 Vegetarian Capsule(s)DSLD:328410
- LifeLinkEGCG Epigallocatechin Gallate 350Green Tea extract · EGCG (Form: from Green Tea extract)350 mgper 1 Capsule(s)DSLD:11770
- NutraBioThermo Fuel V.9Green Tea extract225 mgper 2 Vegetable Capsule(s)DSLD:309319
- NutraBioThermo Fuel V.9 Women's FormulaGreen Tea Leaf Extract · EGCG (Form: from Green Tea leaf extract PlantPart: leaf) (Alt. Name: Epigallocatechin Gallate)142 mgper 2 Vegetable Capsule(s)DSLD:53109
- NutriliteConcentrated Fruits and VegetablesGreen Tea extract45 mgper 1 Tablet(s)DSLD:328190
- NutriliteConcentrated Fruits and VegetablesGreen Tea extract45 mgper 1 Tablet(s)DSLD:328195
- NutriliteConcentrated Fruits and VegetablesGreen Tea extract45 mgper 1 Tablet(s)DSLD:328233
- NutriliteConcentrated Fruits And VegetablesGreen Tea extract45 mgper 1 Tablet(s)DSLD:328149
- Official HCG Diet PlanPAGG Daytime FormulaGreen Tea extract · ECGC (Form: as Green Tea extract)405 mgper 3 Capsule(s)DSLD:218020
- Official HCG Diet PlanRazberi-K KetonesEGCG Green Tea extract Note: 50%50 mgper 1 Capsule(s)DSLD:71504
- Ormus MineralsBlood Sugar Stabilizer80%amount not statedper 4 Capsule(s)DSLD:269136
- ProCaps LaboratoriesAndrew's Five FavoritesGreen Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)200 mgper 2 Capsule(s)DSLD:248401
- ProCaps LaboratoriesAndrew's Five FavoritesGreen Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)200 mgper 3 Capsule(s)DSLD:4673
- ProCaps LaboratoriesMaximum Eye SupportGreen Tea leaf extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)125 mgper 3 Capsule(s)DSLD:69423
- ProCaps LaboratoriesMen's Life Rx Elite Plus Maximum Essential Omega-3Green Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)100 mgper 8 Capsule(s)DSLD:29935
- ProCaps LaboratoriesMen's Life Rx UltimateGreen Tea leaf extract150 mgper 8 Capsule(s)DSLD:4718
- ProCaps LaboratoriesMillion ORAC Standardized ExtractsPolyphenols · White Tea extract (Form: standardized to 90% Polyphenols) PlantPart: bud and leaf20 mgper 1 Capsule(s)DSLD:275275
- ProCaps LaboratoriesMillion ORAC Standardized ExtractsGreen {Tea leaf extract} · Epigallocatechin Gallate (Form: from standardized Green {Tea leaf extract} PlantPart: leaf, and White Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)58 mgper 1 Capsule(s)DSLD:29548
- ProCaps LaboratoriesResveratrol 100 Green Tea EGCG 100 Pomegranate Extract 40:40Green Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)100 mgper 1 Capsule(s)DSLD:57368
- ProCaps LaboratoriesResveratrol- 50 mg EGCG - 100 mgGreen Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)100 mgper 1 Capsule(s)DSLD:4670
- ProCaps LaboratoriesWomen's Life Rx EliteGreen Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)100 mgper 6 Capsule(s)DSLD:29931
- ProCaps LaboratoriesWomen's Life Rx EliteGreen Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)100 mgper 6 Capsule(s)DSLD:4728
- ProCaps LaboratoriesWomen's Life Rx Elite Plus Maximum Essential Omega-3Green Tea Leaf Extract · Epigallocatechin Gallate (Form: from standardized Green Tea leaf extract PlantPart: leaf) (Alt. Name: EGCG)100 mgper 8 Capsule(s)DSLD:29945
- ProCaps LaboratoriesWomen's Life Rx UltimateGreen Tea leaf extract150 mgper 8 Capsule(s)DSLD:4707
- Razberi-KRaspberry KeytonesEGCG Green Tea extract Note: 50%50 mgper 1 Capsule(s)DSLD:19235
- Rexall Sundown NaturalistOne Daily EnergyGreen Tea extract · EGCG Epigallocatechin Gallate (Form: from Green Tea extract PlantPart: leaf Genus: Camellia Species: sinensis)32 mgper 1 Tablet(s)DSLD:72827
- Source NaturalsEGCGGreen Tea leaf extract · EGCG Epigallocatechin Gallate (Form: from Green Tea leaf extract PlantPart: leaf)700 mgper 1 Tablet(s)DSLD:214374
- Source NaturalsEGCG 350 mgGreen Tea Leaf Extract · EGCG (Form: from Green Tea leaf extract PlantPart: leaf) (Alt. Name: Epigallocatechin Gallate)700 mgper 1 Tablet(s)DSLD:214370
- Source NaturalsEGCG 350 mgGreen Tea leaf extract · EGCG Epigallocatechin Gallate (Form: from Green Tea leaf extract PlantPart: leaf)700 mgper 1 Tablet(s)DSLD:273818
- SuperSmartAppetite Control FormulaGreen Tea extract250 mgper 1 Capsule(s)DSLD:332333
- SuperSmartEGCGGreen Tea Extract · standardized to 70% EGCG455 mgper 2 Capsule(s)DSLD:332749
- SuperSmartFlavoLifeGreen Tea leaf extract50 mgper 2 Capsule(s)DSLD:332362
- SuperSmartLung DetoxGreen Tea Leaf Extract50 mgper 2 Capsule(s)DSLD:332393
- Vital AlchemyFit ThroidEpigallocatechin Gallate Note: (50%) (consisting of)200 mgper 1 Capsule(s)DSLD:223140
- Vitamin Research ProductsExtend Core25 mgper 2 Capsule(s)DSLD:33995
- Well At WalgreensGreen Tea90 mgper 1 Caplet(s)DSLD:207266
Label record: NIH Office of Dietary Supplements · CC0
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- (-)-epigallocatechin 3-gallate
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
17 trials
17 registered trials without posted results · Overdue (FDAAA 801): 15
15 past the window2 within it, or no actual date
- NCT05409872completed2026-04-28a university or hospital
- NCT06768086completed2025-09-30a research networkpast the reporting window
- NCT01744587completed2023-05-16a university or hospitalpast the reporting window
- NCT03978052completed2023-03-29a university or hospitalpast the reporting window
- NCT02887950terminated— No benefit at iterim analysis2019-09a university or hospitalpast the reporting window
- NCT01360320completed2019-05a university or hospitalpast the reporting window
- NCT02015312completed2017-10-11a university or hospitalpast the reporting window
- NCT02731495completed2015-11a university or hospitalpast the reporting window
- NCT01855971completed2015-07-31a university or hospitalpast the reporting window
- NCT01923597completed2015-03a university or hospitalpast the reporting window
- NCT00951834completed2015-02a university or hospitalpast the reporting window
- NCT00951964completed2013-07a university or hospitalpast the reporting window
Show the remaining 5
- NCT00525668completed2012-11a university or hospitalpast the reporting window
- NCT01417312completed2012-11a university or hospitalpast the reporting window
- NCT01394796completed2011-02a university or hospitalpast the reporting window
- NCT01687556completed2006-06a university or hospitalpast the reporting window
- NCT00611416completedno completion datea university or hospital
Papers screened
2,179 papers
- Compound
- (-)-epigallocatechin 3-gallate
- Screened
- 2,179
- Admitted
- 12
- Discarded
- 1,586
- Not read
- 581
- Showing
- 200 of 2,179
Produced a finding12 papers
and 12 more.
Read and discarded1,586 papers
- PMID:14744438cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:15284456cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:15944708cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:16224044cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:16452165cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:17302199cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:17765889cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:18048393cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:18426918cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:18668037cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:18668040cited by PMID:25559244; not about the subject it would be filed under2026-10-17
- PMID:18955434cited by PMID:25559244; not about the subject it would be filed under2026-10-17
and 1,574 more.
Not read yet581 papers
- PMID:185917652026-10-15
- PMID:189531102026-10-15
- PMID:172964912026-10-15
- PMID:175042022026-10-15
and 577 more.
Measured, not recorded
- Compound
- (-)-epigallocatechin 3-gallate
- Endpoints measured
- 1,211 endpoints
- Recorded as a finding
- No
Show what was measured
AUC and Cmax of EGCG across ascending oral doses of EGCG
increases
The AUC and maximum plasma concentration (Cmax) of EGCG after the 800-mg dose of EGCG were found to be significantly higher than those after the 200- and 400-mg dose.
PMID:11205489 · one of two readings recorded this
AUC and Cmax of EGCG across ascending oral doses of Polyphenon E
increases
The AUC and Cmax of EGCG after the 800-mg dose of Polyphenon E were significantly higher than those after the three lower doses.
PMID:11205489 · one of two readings recorded this
AUC and Cmax of EGCG after EGCG administration, across dose levels
increases
The AUC and maximum plasma concentration (Cmax) of EGCG after the 800-mg dose of EGCG were found to be significantly higher than those after the 200- and 400-mg dose.
PMID:11205489 · one of two readings recorded this
AUC and Cmax of EGCG after Polyphenon E administration, across dose levels
increases
The AUC and Cmax of EGCG after the 800-mg dose of Polyphenon E were significantly higher than those after the three lower doses.
PMID:11205489 · one of two readings recorded this
pharmacokinetic characteristics (AUC) of EGCG, EGCG versus Polyphenon E administration
no effect
There were no significant differences in the pharmacokinetic characteristics of EGCG between the two study medications.
PMID:11205489 · one of two readings recorded this
plasma AUC of unchanged EGCG after EGCG versus Polyphenon E administration
no effect
There were no significant differences in the pharmacokinetic characteristics of EGCG between the two study medications.
PMID:11205489 · one of two readings recorded this
plasma detection of EGC and EC after EGCG versus Polyphenon E administration
no effect
EGC and EC were not detected in plasma after EGCG administration and were present at low/undetectable levels after Polyphenon E administration.
PMID:11205489 · one of two readings recorded this
plasma EGC and EC (and their glucuronide/sulfate conjugates) after EGCG versus Polyphenon E administration
EGC and EC were not detected in plasma after EGCG administration and were present at low/undetectable levels after Polyphenon E administration.
PMID:11205489 · one of two readings recorded this
plasma pharmacokinetics of unchanged EGCG (AUC and Cmax) measured by HPLC with coulometric electrode array detection, after single oral doses of EGCG and of Polyphenon E
no effect
Not recorded as a finding: the comparison was against another active treatment
There were no significant differences in the pharmacokinetic characteristics of EGCG between the two study medications.
PMID:11205489 · one of two readings recorded this
systemic availability (AUC) and Cmax of EGCG after single oral dose administration of EGCG versus Polyphenon E, by HPLC with coulometric electrode array detection
no effect
Not recorded as a finding: the comparison was against another active treatment
There were no significant differences in the pharmacokinetic characteristics of EGCG between the two study medications.
PMID:11205489 · one of two readings recorded this
AUC(0-infinity) of total EGCG
442-10,368 ng.h/ml
The mean AUC(0-infinity) of total EGCG varied between 442 and 10,368 ng.h/ml.
PMID:12760312 · one of two readings recorded this
Cmax and Tmax of EGCG
Cmax 130-3392 ng/ml, observed after 1.3-2.2 h
The according mean Cmax values ranged from 130 to 3392 ng/ml and were observed after 1.3-2.2 h.
PMID:12760312 · one of two readings recorded this
plasma AUC(0-infinity) of total EGCG across ascending single oral doses
442 to 10,368 ng.h/ml
The mean AUC(0-infinity) of total EGCG varied between 442 and 10,368 ng.h/ml.
PMID:12760312 · one of two readings recorded this
plasma pharmacokinetics of single ascending oral doses of EGCG (AUC(0-infinity), Cmax, Tmax, t1/2z)
442-10,368 ng.h/ml (AUC(0-infinity)) across the six dose levels
Not recorded as a finding: the comparison was against another active treatment
The mean AUC(0-infinity) of total EGCG varied between 442 and 10,368 ng.h/ml.
PMID:12760312 · one of two readings recorded this
safety and tolerability of single oral EGCG doses up to 1600 mg
safe and very well tolerated
Single oral doses of EGCG up to 1600 mg were safe and very well tolerated.
PMID:12760312 · one of two readings recorded this
safety and tolerability of single oral EGCG doses
Single oral doses of EGCG up to 1600 mg were safe and very well tolerated.
PMID:12760312 · one of two readings recorded this
terminal elimination half-life (t1/2z) of EGCG
1.9-4.6 h
The mean t1/2z values were seen between 1.9 and 4.6 h.
PMID:12760312 · one of two readings recorded this
adverse event incidence (excess gas, upset stomach, nausea, heartburn, stomach ache, abdominal pain, dizziness, headache, muscle pain), self-reported over 4 weeks
Not recorded as a finding: the supporting sentence never names the compound
For most events, the incidence reported in the polyphenol-treated groups was not more than that reported in the placebo group.
PMID:12960117 · one of two readings recorded this
plasma-kinetic behaviour of EGCG (absorption, dose linearity, elimination half-life, accumulation factor R) after 10 days' repeated oral dosing at 200, 400 or 800 mg/day
increases
Not recorded as a finding: this platform holds no node for the endpoint
An increase in elimination half-life (t1/2.z) and in the accumulation factor (R) in the 800 mg dosage group indicates dose-dependent saturation of capacity-limited excretion routes or an increase of hepato-duodenal re-circulation.
PMID:15580809 · one of two readings recorded this
Baseline fat intake
increases, p = 0.04, n = 88
Except for HbA1c, which was higher in the EGCG group (P=0·043) and fat intake, which was higher in the placebo group (P=0·040)
PMID:18710606 · one of two readings recorded this
Baseline HbA1c
increases, p = 0.043, n = 88
Except for HbA1c, which was higher in the EGCG group (P=0·043) and fat intake, which was higher in the placebo group (P=0·040)
PMID:18710606 · one of two readings recorded this
Capsules returned per subject (compliance)
unclear, n = 88
Each subject received 112 capsules and on average 3·2 (SD 4·5) capsules per subject (placebo, 4·0 (SD 5·8); EGCG, 2·4 (SD 2·7)) were returned, indicating that >95% of doses were taken
PMID:18710606 · one of two readings recorded this
Diastolic blood pressure, change from baseline
decreases, p = 0.014, n = 88
EGCG treatment was found to reduce diastolic blood pressure (P=0·014)
PMID:18710606 · one of two readings recorded this
diastolic blood pressure, manual sphygmomanometer on the upper arm, semi-recumbent after 5 min rest, mean of second and third of three readings, change from baseline at week 8; also OGTT insulin sensitivity, secretion and glucose tolerance, lipids, mood checklist
decreases, p = 0.014
Not recorded as a finding: a node exists but the paper states a different instrument or population
However, EGCG treatment was found to reduce diastolic blood pressure (P=0·014) (Table 2; Fig. 2).
PMID:18710606 · one of two readings recorded this
diastolic blood pressure, manual upper-arm sphygmomanometer, mean of second and third of three readings at 5 min intervals, semi-recumbent after at least 5 min rest, change from baseline at week 8
decreases, p = 0.014
Not recorded as a finding: a node exists but the paper states a different instrument or population
However, EGCG treatment was found to reduce diastolic blood pressure (P=0·014) (Table 2; Fig. 2).
PMID:18710606 · one of two readings recorded this
Dietary intake (alcohol, carbohydrate, fat, protein, energy)
no effect, n = 88
Over the course of the intervention no significant change in dietary intake measures (g alcohol/carbohydrate/fat/protein or total estimated energy in kJ) was detected
PMID:18710606 · one of two readings recorded this
Gastrointestinal and general health symptom parameters
no effect, n = 88
No significant differences between the EGCG or placebo groups were detected for any of the assessed gastrointestinal and general health parameters (data not shown)
PMID:18710606 · one of two readings recorded this
Glucose tolerance measures (OGTT glucose AUC)
no effect, n = 88
No significant differences were detected between the two groups for any of the insulin sensitivity, insulin secretion or glucose tolerance measures (Table 2)
PMID:18710606 · one of two readings recorded this
Insulin secretion measures (HOMA%B, OGTT insulinogenic index)
no effect, n = 88
No significant differences were detected between the two groups for any of the insulin sensitivity, insulin secretion or glucose tolerance measures (Table 2)
PMID:18710606 · one of two readings recorded this
Insulin sensitivity measures (HOMA-IR, OGTT ISI)
no effect, n = 88
No significant differences were detected between the two groups for any of the insulin sensitivity, insulin secretion or glucose tolerance measures (Table 2)
PMID:18710606 · one of two readings recorded this
Mood: energetic arousal and general arousal (UWIST)
no effect, n = 88
Results for energetic arousal and general arousal did not differ significantly between the two groups
PMID:18710606 · one of two readings recorded this
Mood: hedonic tone (UWIST), across 8 weeks
increases, p = 0.048, n = 88
Across the 8-week period, the EGCG group scored higher on hedonic tone than the placebo group (29·11 (SE 0·44) v. 27·84 (SE 0·46), P=0·048)
PMID:18710606 · one of two readings recorded this
Mood: hedonic tone (UWIST), baseline
no effect, n = 88
the baseline scores for both components (tense arousal, placebo 11·83 (SD 3·99), EGCG 11·29 (SD 3·06); hedonic tone, placebo 29·25 (SD 3·72), EGCG 29·10 (SD 3·68)) were virtually the same for the EGCG and placebo groups
PMID:18710606 · one of two readings recorded this
Mood: tense arousal (UWIST), across 8 weeks
no effect, p = 0.056, n = 88
Although not quite reaching significance the EGCG group also scored lower on tense arousal compared to the placebo group (11·06 (SE 0·47) v. 12·33 (SE 0·45), P=0·056)
PMID:18710606 · one of two readings recorded this
Mood: tense arousal (UWIST), baseline
no effect, n = 88
the baseline scores for both components (tense arousal, placebo 11·83 (SD 3·99), EGCG 11·29 (SD 3·06); hedonic tone, placebo 29·25 (SD 3·72), EGCG 29·10 (SD 3·68)) were virtually the same for the EGCG and placebo groups
PMID:18710606 · one of two readings recorded this
OGTT insulinogenic index, change from baseline
no effect, n = 87
after removal from the analysis of one subject in the placebo group, displaying an extreme OGTTInsulinogenic index value post-intervention but not at baseline, the difference was no longer significant
PMID:18710606 · one of two readings recorded this
OGTT insulinogenic index, change from baseline
decreases, p = 0.048, n = 88
A significant difference (P=0·048) between the placebo and EGCG groups was detected for OGTTInsulinogenic index (mean change: placebo 11·22 (SE 4·02), EGCG −0·25 (SE 3·97))
PMID:18710606 · one of two readings recorded this
Other metabolic risk factors (BMI, waist circumference, body fat, cholesterol, TAG)
no effect, n = 88
The EGCG intervention had no significant effect on any of the other metabolic risk factors measured (Table 2)
PMID:18710606 · one of two readings recorded this
Proportion classified as obese (BMI >= 30) at baseline
no effect, n = 88
It was found that 57·1% of the placebo group and 58·7% of the EGCG group were classified as obese (BMI ≥ 30)
PMID:18710606 · one of two readings recorded this
Proportion with combined impaired fasting glucose and glucose tolerance at baseline
no effect, n = 88
19·5 and 20·0% with impaired fasting glucose; 7·3 and 6·7% with impaired glucose tolerance; 4·9 and 8·9% with combined impairments (impaired fasting glucose and impaired glucose tolerance), for placebo and EGCG groups, respectively
PMID:18710606 · one of two readings recorded this
Proportion with impaired fasting glucose at baseline
no effect, n = 88
19·5 and 20·0% with impaired fasting glucose; 7·3 and 6·7% with impaired glucose tolerance; 4·9 and 8·9% with combined impairments (impaired fasting glucose and impaired glucose tolerance), for placebo and EGCG groups, respectively
PMID:18710606 · one of two readings recorded this
Proportion with impaired glucose tolerance at baseline
no effect, n = 88
19·5 and 20·0% with impaired fasting glucose; 7·3 and 6·7% with impaired glucose tolerance; 4·9 and 8·9% with combined impairments (impaired fasting glucose and impaired glucose tolerance), for placebo and EGCG groups, respectively
PMID:18710606 · one of two readings recorded this
Systolic blood pressure, change from baseline
no effect, p = 0.096, n = 88
Although not significant, a trend towards a reduction in systolic blood pressure (P=0·096) was also noted
PMID:18710606 · one of two readings recorded this
development of prostate cancer in men with high-grade PIN given green tea catechins
decreases, n = 30
Only 1 patient developed prostate cancer, whereas 9 of the 30 patients with high-grade PIN in the placebo group developed prostate cancer.
PMID:19472429 · one of two readings recorded this
oesophageal cancer risk by green tea consumption in a case-control study, stratified by sex and smoking status
decreases
However, no protective effect was found in men, who were mostly smokers.
PMID:19472429 · one of two readings recorded this
plasma oxidized low-density lipoprotein in healthy volunteers supplemented with tea catechins
decreases, 18% decrease
Supplementation of the diets of healthy human volunteers with tea catechins (500 mg per day) for 4 weeks resulted in an 18% decrease in plasma oxidized low-density lipoprotein compared with the control.
PMID:19472429 · one of two readings recorded this
Body mass
no effect, p = 0.64, n = 19
Body mass was not different between trials (71.3 ± 2.6 vs. 71.6 ± 2.6 kg; P = 0.64)
PMID:19952844 · one of two readings recorded this
Absolute VO2max, males versus females
unclear, p = 0.006, n = 19
Although not a primary focus of this investigation, absolute VO2max was greater in males compared with females (P = 0.006)
PMID:19952844 · one of two readings recorded this
Heart rate during maximal exercise (cardiac output determination)
no effect, p = 0.56, n = 11
Short-term consumption of EGCG did not affect heart rate, stroke volume, or cardiac output during maximal exercise (Table 3; all P > 0.56)
PMID:19952844 · one of two readings recorded this
Heart rate immediately before exercise
decreases, p = 0.05, n = 11
Immediately prior to exercise heart rate was lower with EGCG (mean change: -6 ± 3 beats·min-1; P < 0.05)
PMID:19952844 · one of two readings recorded this
heart rate, stroke volume and cardiac output at maximal exercise by open-circuit acetylene breathing
no effect
Not recorded as a finding: No outcome node for maximal cardiac output or stroke volume.
Short-term consumption of EGCG did not affect heart rate, stroke volume, or cardiac output during maximal exercise (Table 3; all P > 0.56).
PMID:19952844 · one of two readings recorded this
maximal cardiac output by open-circuit acetylene breathing, subset of 11
no effect, heart rate, stroke volume and cardiac output at maximal exercise unaffected
Not recorded as a finding: no outcome node for cardiac output
Short-term consumption of EGCG did not affect heart rate, stroke volume, or cardiac output during maximal exercise (Table 3; all P > 0.56).
PMID:19952844 · one of two readings recorded this
Maximal cardiac output
no effect, p = 0.56, n = 11
Short-term consumption of EGCG did not affect heart rate, stroke volume, or cardiac output during maximal exercise (Table 3; all P > 0.56)
PMID:19952844 · one of two readings recorded this
Maximal heart rate during cardiac output determination vs during VO2max test
no effect, p = 0.24, n = 11
Maximal heart rate obtained during cardiac output determination did not differ from maximal heart rate during determination of VO2max for either placebo (179 ± 3 vs. 180 ± 3 beats·min-1; P = 0.27) or EGCG (177 ± 3 vs. 179 ± 3 beats·min-1; P = 0.24)
PMID:19952844 · one of two readings recorded this
Maximal heart rate during cardiac output determination vs during VO2max test
no effect, p = 0.27, n = 11
Maximal heart rate obtained during cardiac output determination did not differ from maximal heart rate during determination of VO2max for either placebo (179 ± 3 vs. 180 ± 3 beats·min-1; P = 0.27) or EGCG (177 ± 3 vs. 179 ± 3 beats·min-1; P = 0.24)
PMID:19952844 · one of two readings recorded this
Maximal heart rate during VO2max test
no effect, p = 0.87, n = 19
Maximal work rate (P = 0.98), maximal respiratory exchange ratio (P = 0.27), and maximal heart rate were unaffected (P = 0.87)
PMID:19952844 · one of two readings recorded this
Maximal oxygen uptake (VO2max)
increases, p = 0.04, n = 19
Compared with placebo, short-term EGCG consumption increased VO2max (Table 2; mean change = +0.136 ± 0.064 L·min-1; P = 0.04
PMID:19952844 · one of two readings recorded this
Maximal respiratory exchange ratio
no effect, p = 0.27, n = 19
Maximal work rate (P = 0.98), maximal respiratory exchange ratio (P = 0.27), and maximal heart rate were unaffected (P = 0.87)
PMID:19952844 · one of two readings recorded this
Maximal work rate
no effect, p = 0.98, n = 19
Maximal work rate (P = 0.98), maximal respiratory exchange ratio (P = 0.27), and maximal heart rate were unaffected (P = 0.87)
PMID:19952844 · one of two readings recorded this
Relation of baseline (placebo) VO2max to change in VO2max with EGCG
no effect, p = 0.97, n = 19
Baseline (placebo) VO2max was not related to the magnitude of change in VO2max with EGCG (r2 = 0.00, P = 0.97)
PMID:19952844 · one of two readings recorded this
Relation of change in TVE to change in maximal cardiac output
no effect, p = 0.85, n = 11
the change in TVE with EGCG was not related to the change in VO2max (r = 0.02, P = 0.95) or maximal cardiac output (r = -0.08, P = 0.85)
PMID:19952844 · one of two readings recorded this
Relation of change in TVE to change in VO2max
no effect, p = 0.95, n = 16
the change in TVE with EGCG was not related to the change in VO2max (r = 0.02, P = 0.95) or maximal cardiac output (r = -0.08, P = 0.85)
PMID:19952844 · one of two readings recorded this
Relation of EGCG-induced changes in maximal cardiac output and VO2max
no effect, p = 0.76, n = 11
maximal cardiac output and VO2max were strongly related (r2 = 0.88, P < 0.001), however the changes in maximal cardiac output and VO2max with EGCG were unrelated (r2 = 0.01, P = 0.76)
PMID:19952844 · one of two readings recorded this
Relation of maximal cardiac output to VO2max
unclear, p = 0.001, n = 11
maximal cardiac output and VO2max were strongly related (r2 = 0.88, P < 0.001), however the changes in maximal cardiac output and VO2max with EGCG were unrelated (r2 = 0.01, P = 0.76)
PMID:19952844 · one of two readings recorded this
Stroke volume and cardiac output immediately before exercise
no effect, p = 0.08, n = 11
stroke volume and cardiac output were unaffected (both P > 0.08)
PMID:19952844 · one of two readings recorded this
Stroke volume during maximal exercise
no effect, p = 0.56, n = 11
Short-term consumption of EGCG did not affect heart rate, stroke volume, or cardiac output during maximal exercise (Table 3; all P > 0.56)
PMID:19952844 · one of two readings recorded this
Subjects with increased VO2max on EGCG
increases, n = 19
This increase occurred in 14 out of 19 subjects
PMID:19952844 · one of two readings recorded this
Ventilatory threshold, males versus females
unclear, p = 0.02, n = 16
Ventilatory threshold was greater in males compared with females (P = 0.02)
PMID:19952844 · one of two readings recorded this
VO2 at the ventilatory threshold, breath-by-breath indirect calorimetry
no effect, mean change -0.10 L/min, decreased in 12 of 16 subjects, p = 0.06
Not recorded as a finding: No outcome node for ventilatory threshold; the result was also not significant.
Contrary to our hypothesis the VO2 at TVE was decreased in 12 out of 16 subjects following short-term consumption of EGCG (Table 2; mean change = -0.10 ± 0.05 L·min-1) however, this decrease was not statistically significant (P = 0.06).
PMID:19952844 · one of two readings recorded this
VO2 at TVE by sex, placebo versus EGCG interaction
no effect, p = 0.79
Placebo: Male 1.77 ± 0.16 vs. Female 1.32 ± 0.07 L·min-1; EGCG: Male 1.68 ± 0.13 vs. Female 1.21 ± 0.07 L·min-1; P = 0.79
PMID:19952844 · one of two readings recorded this
VO2 at TVE by sex, placebo versus EGCG interaction
no effect, p = 0.79
Placebo: Male 1.77 ± 0.16 vs. Female 1.32 ± 0.07 L·min-1; EGCG: Male 1.68 ± 0.13 vs. Female 1.21 ± 0.07 L·min-1; P = 0.79
PMID:19952844 · one of two readings recorded this
VO2 at ventilatory threshold, breath-by-breath indirect calorimetry
no effect, VO2 at TVE decreased in 12 of 16 subjects, mean change -0.10 L/min, not statistically significant, p = 0.06
Not recorded as a finding: no outcome node for ventilatory threshold
Contrary to our hypothesis the VO2 at TVE was decreased in 12 out of 16 subjects following short-term consumption of EGCG (Table 2; mean change = -0.10 ± 0.05 L·min-1) however, this decrease was not statistically significant (P = 0.06).
PMID:19952844 · one of two readings recorded this
VO2 at ventilatory threshold (TVE)
no effect, p = 0.06, n = 16
Contrary to our hypothesis the VO2 at TVE was decreased in 12 out of 16 subjects following short-term consumption of EGCG (Table 2; mean change = -0.10 ± 0.05 L·min-1) however, this decrease was not statistically significant (P = 0.06)
PMID:19952844 · one of two readings recorded this
VO2max by sex, placebo versus EGCG interaction
no effect, p = 0.51, n = 8
Placebo: Male 3.55 ± 0.23 vs. Female 2.53 ± 0.15 L min-1; EGCG: Male 3.65 ± 0.24 vs. Female 2.72 ± 0.23 L·min-1; P = 0.51
PMID:19952844 · one of two readings recorded this
VO2max by sex, placebo versus EGCG interaction
no effect, p = 0.51, n = 11
Placebo: Male 3.55 ± 0.23 vs. Female 2.53 ± 0.15 L min-1; EGCG: Male 3.65 ± 0.24 vs. Female 2.72 ± 0.23 L·min-1; P = 0.51
PMID:19952844 · one of two readings recorded this
VO2max relative to body mass
increases, n = 19
thus when expressed relative to body mass the increase in VO2max with EGCG was consistent with the increase in absolute VO2max (44.1 ± 2.6 vs. 45.8 ± 2.6 mL·kg-1·min-1)
PMID:19952844 · one of two readings recorded this
apoptosis in ELT3 cells
increases
Enhanced apoptosis was observed in ELT3 cells treated with ≥ 50 μM EGCG when compared to vehicle treated cells
PMID:20074693 · one of two readings recorded this
Cdk4 protein in ELT3 cells
decreases, p = 0.05
≥50uM EGCG significantly decreased PCNA and Cdk4 protein expression, compared to vehicle control (p<0.05)
PMID:20074693 · one of two readings recorded this
Cdk4 protein in tumor tissue
decreases, p = 0.05
1.25mg/mouse/day of EGCG oral consumption significantly decreased PCNA and Cdk4 protein expression compared to water-fed control group at 4 and 8 weeks post-treatment (p<0.05)
PMID:20074693 · one of two readings recorded this
cell morphology (blebbing, apoptotic vesicles) at 72 h
modulates
The cell morphology changed markedly as blebbing formation and apoptotic vesicles were observed in cells treated with 100μM EGCG for 72 h
PMID:20074693 · one of two readings recorded this
ELT3 cell proliferation, 200 μM EGCG at 24 h
decreases, p = 0.05
The inhibitory effect of 200 μM EGCG was observed after 24 h treatment (p<0.05)
PMID:20074693 · one of two readings recorded this
ELT3 cell proliferation, 200 μM EGCG at 72 h
decreases
with 40% reduction in cell proliferation observed in cells after exposure to 200μM EGCG for 72 h
PMID:20074693 · one of two readings recorded this
ELT3 cell proliferation, 50 μM and above EGCG, day 3 to day 7
decreases, p = 0.05
The significant inhibitory effect of ≥50μM EGCG on ELT3 cells was observed by day 3 and continued till day 7 (p<0.05, Figure2)
PMID:20074693 · one of two readings recorded this
PCNA-positive cells per high power field at 4 weeks
decreases
The percentage of positive cells for PCNA was 72.88% ± 4.21% and 58.69% ± 3.55% per high power field in water-fed control and EGCG treated at 4 weeks, respectively
PMID:20074693 · one of two readings recorded this
PCNA-positive cells per high power field at 8 weeks
decreases
The number of positive cells for PCNA was 99.6% ± 8.77% and 71.3% ± 9.38% per high power field in the control group and EGCG treated group at 8 weeks, respectively
PMID:20074693 · one of two readings recorded this
PCNA protein in ELT3 cells
decreases, p = 0.05
≥50uM EGCG significantly decreased PCNA and Cdk4 protein expression, compared to vehicle control (p<0.05)
PMID:20074693 · one of two readings recorded this
PCNA protein in tumor tissue
decreases, p = 0.05
1.25mg/mouse/day of EGCG oral consumption significantly decreased PCNA and Cdk4 protein expression compared to water-fed control group at 4 and 8 weeks post-treatment (p<0.05)
PMID:20074693 · one of two readings recorded this
tumor volume at 4 weeks, EGCG 1.25 mg/mouse/day
decreases, p = 0.05
On the other hand, in the EGCG treated group, tumors were significantly smaller, 31±5 mm3 and 129±54 mm3 (p<0.05), at the same time points
PMID:20074693 · one of two readings recorded this
tumor volume at 4 weeks, water-fed control
In the control animals, the tumor volume reached 46±5 mm3 and 288±57 mm3 at 4 weeks and 8 weeks post ELT3 cells inoculation, respectively
PMID:20074693 · one of two readings recorded this
tumor volume at 8 weeks, EGCG 1.25 mg/mouse/day
decreases, p = 0.05
On the other hand, in the EGCG treated group, tumors were significantly smaller, 31±5 mm3 and 129±54 mm3 (p<0.05), at the same time points
PMID:20074693 · one of two readings recorded this
tumor volume at 8 weeks, water-fed control
In the control animals, the tumor volume reached 46±5 mm3 and 288±57 mm3 at 4 weeks and 8 weeks post ELT3 cells inoculation, respectively
PMID:20074693 · one of two readings recorded this
tumor weight at 4 weeks
decreases, p = 0.05
Tumor weight in EGCG treated group was 0.0036 ± 0.0027g and 0.11 ± 0.04g, versus 0.077± 0.0045 and 0.29 ± 0.06g in water-fed group 4 weeks and 8 post-treatment, respectively (p<0.05)
PMID:20074693 · one of two readings recorded this
tumor weight at 8 weeks
decreases, p = 0.05
Tumor weight in EGCG treated group was 0.0036 ± 0.0027g and 0.11 ± 0.04g, versus 0.077± 0.0045 and 0.29 ± 0.06g in water-fed group 4 weeks and 8 post-treatment, respectively (p<0.05)
PMID:20074693 · one of two readings recorded this
tumour volume (caliper, three dimensions) and tumour weight of ELT3 rat leiomyoma xenografts in nude mice given 1.25 mg EGCG/mouse/day in drinking water; ELT3 cell proliferation by MTT; PCNA and Cdk4 protein by Western blot
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Tumor weight in EGCG treated group was significantly less than those of water-fed group after 4 weeks or 8 weeks of treatment (p<0.05).
PMID:20074693 · one of two readings recorded this
uterine leiomyoma tumour volume by caliper and tumour weight in nude mice bearing ELT3 xenografts
decreases
Not recorded as a finding: no_outcome_node: no xenograft tumour size or weight outcome in the list
On the other hand, in the EGCG treated group, tumors were significantly smaller, 31±5 mm3 and 129±54 mm3 (p<0.05), at the same time points.
PMID:20074693 · one of two readings recorded this
HDL cholesterol
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
Triglycerides
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
Diastolic blood pressure
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
Fasting glucose
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
Leptin:adiponectin ratio
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
plasma adiponectin, CRP, IL-6, IL-1beta, sVCAM-1, sICAM-1, leptin by ELISA, serum amyloid A by ELISA, and features of metabolic syndrome after 8 weeks
no effect
Not recorded as a finding: the intervention held more than the compound
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group (Table 2).
PMID:20605696 · one of two readings recorded this
plasma adiponectin, CRP, IL-6, IL-1beta, sVCAM-1, sICAM-1, leptin by R&D ELISA and serum amyloid A by ELISA after 8 weeks
no effect, not significantly affected by green tea beverage or extract versus age and gender-matched no treatment
Not recorded as a finding: the intervention held more than the compound
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group (Table 2).
PMID:20605696 · one of two readings recorded this
Plasma adiponectin
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Plasma C-reactive protein (CRP)
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Plasma IL-1β
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Plasma IL-6, versus no treatment
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Plasma IL-6
no effect, p = 0.3, n = 11
However, the green tea beverage group showed a non-significant decrease in IL-6 levels (37%, p=0.3) compared to baseline
PMID:20605696 · one of two readings recorded this
Plasma leptin
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Plasma serum amyloid A (SAA)
decreases, p = 0.005, n = 11
Pair wise comparisons showed a significant decrease in plasma SAA in green tea beverage (14.4%, p<0.005) and green tea extract (24.5%, p<0.005) groups versus no treatment subjects at eight weeks of the study (Table 2)
PMID:20605696 · one of two readings recorded this
Plasma serum amyloid A (SAA)
decreases, p = 0.005, n = 7
Pair wise comparisons showed a significant decrease in plasma SAA in green tea beverage (14.4%, p<0.005) and green tea extract (24.5%, p<0.005) groups versus no treatment subjects at eight weeks of the study (Table 2)
PMID:20605696 · one of two readings recorded this
Plasma sICAM-1
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Plasma sVCAM-1
no effect
Plasma concentrations of adiponectin, CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, leptin and leptin: adiponectin ratio were not significantly affected by green tea beverage or extract supplementation for eight weeks versus age and gender-matched no treatment group
PMID:20605696 · one of two readings recorded this
Prevalence of elevated blood pressure or on blood pressure medication among subjects
highest for low HDL (94%), followed by enlarged waist circumference (91%), elevated systolic and/or diastolic blood pressure or on blood pressure medications (71%), elevated triglycerides (54%), and impaired fasting glucose (20%)
PMID:20605696 · one of two readings recorded this
Prevalence of elevated triglycerides among subjects
highest for low HDL (94%), followed by enlarged waist circumference (91%), elevated systolic and/or diastolic blood pressure or on blood pressure medications (71%), elevated triglycerides (54%), and impaired fasting glucose (20%)
PMID:20605696 · one of two readings recorded this
Prevalence of enlarged waist circumference among subjects
highest for low HDL (94%), followed by enlarged waist circumference (91%), elevated systolic and/or diastolic blood pressure or on blood pressure medications (71%), elevated triglycerides (54%), and impaired fasting glucose (20%)
PMID:20605696 · one of two readings recorded this
Prevalence of impaired fasting glucose among subjects
highest for low HDL (94%), followed by enlarged waist circumference (91%), elevated systolic and/or diastolic blood pressure or on blood pressure medications (71%), elevated triglycerides (54%), and impaired fasting glucose (20%)
PMID:20605696 · one of two readings recorded this
Prevalence of low HDL among subjects
highest for low HDL (94%), followed by enlarged waist circumference (91%), elevated systolic and/or diastolic blood pressure or on blood pressure medications (71%), elevated triglycerides (54%), and impaired fasting glucose (20%)
PMID:20605696 · one of two readings recorded this
Safety laboratory parameters (AST, ALT, BUN, creatinine, Hb, platelets, WBC, electrolytes, albumin, total protein, TSH)
no effect
Plasma concentrations of safety parameters including AST, ALT, BUN, creatinine, Hb, platelets, WBC, electrolytes, albumin, total protein, and TSH remained unaltered by green tea beverage or extract supplementation for all participants
PMID:20605696 · one of two readings recorded this
Systolic blood pressure
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
Waist circumference
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
IL-6-induced endothelial tube formation and angiogenesis
decreases
Furthermore, EGCG inhibited IL-6 induced vascular endothelial cell proliferation and tube formation in vitro and angiogenesis in vitro
PMID:21633597 · one of two readings recorded this
IL-6-induced vascular endothelial cell proliferation
decreases
Furthermore, EGCG inhibited IL-6 induced vascular endothelial cell proliferation and tube formation in vitro and angiogenesis in vitro
PMID:21633597 · one of two readings recorded this
IL-6-induced VEGF expression
no effect
However, PD98059 and LY294002 did not change VEGF expression induced by IL-6
PMID:21633597 · one of two readings recorded this
Stat3 activation (IL-6-induced)
decreases
EGCG dose-dependently inhibited Stat3 activation induced by IL-6
PMID:21633597 · one of two readings recorded this
Stat3-DNA binding activity
decreases
EGCG inhibited Stat3 nucleus translocation, and Stat3-DNA binding activity was also markedly decreased by EGCG
PMID:21633597 · one of two readings recorded this
Stat3 nuclear translocation
decreases
EGCG inhibited Stat3 nucleus translocation, and Stat3-DNA binding activity was also markedly decreased by EGCG
PMID:21633597 · one of two readings recorded this
total Stat3 expression
no effect
EGCG dose-dependently inhibited Stat3 activation induced by IL-6, but did not change the total Stat3 expression
PMID:21633597 · one of two readings recorded this
VEGF expression and secretion (IL-6-induced)
decreases
When treated with EGCG, VEGF expression and secretion were dose-dependently decreased
PMID:21633597 · one of two readings recorded this
VEGF expression in tumor cells (EGCG or AG490 versus unstimulated level)
decreases
When treated with EGCG or AG490, VEGF expressions were reduced to the level or an even lower level in the tumor cells not stimulated with IL-6
PMID:21633597 · one of two readings recorded this
VEGF expression (protein, cell lysate) after IL-6 stimulation
increases
After stimulation with IL-6, VEGF expression was apparently up-regulated and a 2.4-fold increase was observed
PMID:21633597 · one of two readings recorded this
VEGF mRNA expression after IL-6 stimulation
increases
IL-6 also increased VEGF mRNA expression by 3.1 folds
PMID:21633597 · one of two readings recorded this
VEGF mRNA expression (IL-6-induced)
decreases
EGCG treatment suppressed VEGF mRNA expression in a dose-dependent manner
PMID:21633597 · one of two readings recorded this
VEGF protein secretion in AGS cell conditioned medium, ELISA; VEGF mRNA by RT-PCR
decreases
Not recorded as a finding: no outcome node for in vitro VEGF expression; recorded here because the paper yielded a mechanism claim
EGCG treatment suppressed VEGF mRNA expression in a dose-dependent manner.
PMID:21633597 · one of two readings recorded this
VEGF secretion in conditioned medium after IL-6 stimulation
increases
VEGF secretion in the conditioned medium was also increased by 2.8 folds
PMID:21633597 · one of two readings recorded this
fasting blood glucose, end of 16 weeks
decreases, 18.5% lower than HF mice
Not recorded as a finding: the only sentences use the arm label HFE or say 'blunted the high fat diet-mediated hyperglycemia', and no Methods text was supplied to define HFE
At the end of the experiment, the fasting blood glucose of HFE mice was 18.5% lower than HF mice.
PMID:21779555 · one of two readings recorded this
fasting blood glucose of high fat-fed mice, HFE versus HF
decreases, the fasting blood glucose of HFE mice was 18.5% lower than HF mice
Not recorded as a finding: arm label HFE is not defined in the text supplied (no Methods), and the sentence does not name EGCG, so it is not self-supporting
At the end of the experiment, the fasting blood glucose of HFE mice was 18.5% lower than HF mice.
PMID:21779555 · one of two readings recorded this
fasting plasma insulin
decreases, 25.3% decrease compared to HF
Not recorded as a finding: no outcome node for fasting insulin
Treatment with EGCG also significantly decreased fasting plasma insulin (25.3% decrease) compared to HF (Table 2).
PMID:21779555 · both readings recorded this
fasting plasma insulin
decreases
Treatment with EGCG also significantly decreased fasting plasma insulin (25.3% decrease) compared to HF (Table 2)
PMID:21779555 · one of two readings recorded this
fecal lipid concentration
increases
average fecal lipid concentration of 8.6 and 10.8 mg/g in HF and HFE, respectively
PMID:21779555 · one of two readings recorded this
fecal lipid content, gravimetric
increases, significantly increased by 20.4% with EGCG treatment compared to HF control group (p < 0.05)
Not recorded as a finding: no_outcome_node: no fecal lipid outcome in the list
The average fecal lipid content significantly increased by 20.4% with EGCG treatment compared to HF control group (p < 0.05).
PMID:21779555 · one of two readings recorded this
fecal lipid content
increases, p = 0.05
The average fecal lipid content significantly increased by 20.4% with EGCG treatment compared to HF control group (p < 0.05)
PMID:21779555 · one of two readings recorded this
final body weight
decreases, p = 0.05
By contrast high fat-fed mice treated with EGCG showed a 21.7% reduction in the rate of body weight gain and a 9.4% decrease in final body weight (p < 0.05, Table 1)
PMID:21779555 · one of two readings recorded this
final fasting blood glucose
increases
HF mice had a 42.4% increase in final fasting blood glucose compared to LF mice
PMID:21779555 · one of two readings recorded this
final fasting blood glucose
decreases
At the end of the experiment, the fasting blood glucose of HFE mice was 18.5% lower than HF mice
PMID:21779555 · one of two readings recorded this
food intake
no effect
Overall, there was no significant difference in the food intake between the treatment groups (data not shown)
PMID:21779555 · one of two readings recorded this
hepatic lipidosis severity score
decreases, p = 0.05
Semi-quantitative analysis of hepatic lipidosis showed a reduction in severity score from 4.8 ± 0.1 to 3.5 ± 0.5 in HFE mice (p < 0.05)
PMID:21779555 · one of two readings recorded this
HOMA-IR computed from final fasting insulin and glucose
decreases, 33.9% decrease in HFE mice compared to HF mice
Not recorded as a finding: arm label HFE is not defined in the text supplied, and the constant and input units are not stated
This increase in insulin resistance was blunted in HFE mice (33.9% decrease compared to HF mice) (Table 2, p < 0.05).
PMID:21779555 · one of two readings recorded this
HOMA-IR from final fasting insulin and glucose
decreases, 33.9% decrease compared to HF mice
Not recorded as a finding: arm label HFE not defined by any supplied Methods sentence
This increase in insulin resistance was blunted in HFE mice (33.9% decrease compared to HF mice) (Table 2, p < 0.05).
PMID:21779555 · one of two readings recorded this
insulin resistance (HOMA-IR)
increases
HF mice had an 88.6% increase in insulin resistance compared to LF fed mice
PMID:21779555 · one of two readings recorded this
insulin resistance (HOMA-IR)
decreases, p = 0.05
This increase in insulin resistance was blunted in HFE mice (33.9% decrease compared to HF mice) (Table 2, p < 0.05)
PMID:21779555 · one of two readings recorded this
liver triglycerides
decreases
Liver triglycerides were reduced by 27% in HFE compared to HF
PMID:21779555 · one of two readings recorded this
liver weight
increases
In HF mice, liver weight was increased by 26.1% compared to LF mice
PMID:21779555 · one of two readings recorded this
liver weight
decreases
the mean liver weight of the EGCG treated mice was 22% less than the high fat-fed mice
PMID:21779555 · one of two readings recorded this
plasma ALT
decreases, decreased by 50% in HFE compared to HF control mice
Not recorded as a finding: arm label HFE is not defined in the text supplied, so the sentence is not self-supporting
Plasma ALT levels were decreased by 50% in HFE compared to HF control mice.
PMID:21779555 · both readings recorded this
plasma ALT
increases
Average plasma ALT levels in LF and HF mice were 3.3 and 100.1 U/L, respectively
PMID:21779555 · one of two readings recorded this
plasma ALT
decreases
Plasma ALT levels were decreased by 50% in HFE compared to HF control mice
PMID:21779555 · one of two readings recorded this
rate of body weight gain
decreases, p = 0.05
By contrast high fat-fed mice treated with EGCG showed a 21.7% reduction in the rate of body weight gain and a 9.4% decrease in final body weight (p < 0.05, Table 1)
PMID:21779555 · one of two readings recorded this
skeletal muscle mcad expression
increases
We found that, compared to high fat-fed controls, EGCG-treated mice had higher expression of mcad (1.4-fold increase), nrf1 (1.5-fold increase), ucp3 (1.9-fold increase) and pparα (1.9-fold increase)
PMID:21779555 · one of two readings recorded this
skeletal muscle nrf1 expression
increases
We found that, compared to high fat-fed controls, EGCG-treated mice had higher expression of mcad (1.4-fold increase), nrf1 (1.5-fold increase), ucp3 (1.9-fold increase) and pparα (1.9-fold increase)
PMID:21779555 · one of two readings recorded this
skeletal muscle pparα expression
increases
We found that, compared to high fat-fed controls, EGCG-treated mice had higher expression of mcad (1.4-fold increase), nrf1 (1.5-fold increase), ucp3 (1.9-fold increase) and pparα (1.9-fold increase)
PMID:21779555 · one of two readings recorded this
skeletal muscle ucp3 expression
increases
We found that, compared to high fat-fed controls, EGCG-treated mice had higher expression of mcad (1.4-fold increase), nrf1 (1.5-fold increase), ucp3 (1.9-fold increase) and pparα (1.9-fold increase)
PMID:21779555 · one of two readings recorded this
weight of retroperitoneal and epididymal fat pads
no effect
Not recorded as a finding: fat-mass node is total adipose tissue mass; individual fat pads, data not shown
Interestingly, there was no significant effect of EGCG on the weight of retroperitoneal and epididymal fat pads (data not shown).
PMID:21779555 · one of two readings recorded this
weight of retroperitoneal and epididymal fat pads
no effect
Interestingly, there was no significant effect of EGCG on the weight of retroperitoneal and epididymal fat pads (data not shown)
PMID:21779555 · one of two readings recorded this
axonal density in entorhinal cortex explants
no effect
Again, there was no significant effect of EGCG or GA alone
PMID:22022398 · one of two readings recorded this
axonal density in entorhinal cortex explants
increases
Axons in slices treated with both GA and EGCG showed a significantly higher density compared to brain slices under control conditions
PMID:22022398 · one of two readings recorded this
BDNF and GDNF secretion in slice culture supernatant
increases
In addition, GA induced the secretion of BDNF and GDNF, which was detected in the supernatants of the brain slice culture by ELISA
PMID:22022398 · one of two readings recorded this
BDNF and GDNF secretion in slice culture supernatant
no effect
No additional increase was seen with EGCG
PMID:22022398 · one of two readings recorded this
clinical severity and disease onset in PLP139-151 induced relapsing-remitting EAE in SJL/L mice, daily 0-5 clinical score; EGCG given alone, with glatiramer acetate, or as vehicle
decreases, the EGCG plus glatiramer acetate combination significantly reduced EAE severity and delayed onset versus vehicle; the paper reports EGCG alone only as a non-significant arm
Not recorded as a finding: this platform holds no node for the endpoint
However, the combination therapy significantly reduced the severity of relapsing-remitting EAE and synergistically delayed the onset of disease compared to vehicle treated animals.
PMID:22022398 · one of two readings recorded this
EAE clinical severity, preventive treatment
decreases, p = 0.05, n = 8
Mean disease score of control, EGCG, GA and the combination therapy group is shown from day 0 to day 45 after immunization (A), * p<0.05 day 13,15–18,20–22,24,26–27, **p<0.01 day 14,19,23,25,28,35–39,42, n = 8 per group
PMID:22022398 · one of two readings recorded this
EAE cumulative disease activity (area under clinical score curve), preventive treatment
decreases, p = 0.05
Cumulative disease activity of control, GA, EGCG and combination therapy group was calculated as the area under the curve of the clinical score plots for each individual animal (C), *p<0.05
PMID:22022398 · one of two readings recorded this
EAE cumulative disease activity, established disease (therapeutic treatment)
decreases
The combination therapy enhanced recovery and prevented long-term neurological deficits, as indicated by significant reductions in the mean clinical score and the cumulative disease activity compared to the vehicle treated group
PMID:22022398 · one of two readings recorded this
EAE disease incidence and severity, preventive treatment
no effect
As expected, treatment with suboptimal doses of GA alone did not significantly decrease disease incidence and severity
PMID:22022398 · one of two readings recorded this
EAE disease onset (percentage of sick mice), preventive treatment
decreases, p = 0.05
Onset of disease in control, GA, EGCG and combination therapy group is presented in a Kaplan-Meier survival curve as percentage of sick mice at a certain day after immunization (B), *p<0.05
PMID:22022398 · one of two readings recorded this
EAE mean clinical score, established disease (therapeutic treatment)
decreases, p = 0.05, n = 6
Mean disease score of control and combination therapy group is shown from day 0 to day 44 after immunization (A), *p<0.05 day 19, 20, 23, 24, 34, n = 6
PMID:22022398 · one of two readings recorded this
number of axons in entorhinal cortex explants
no effect
GA or EGCG alone did not induce a significant increase in the number of neurites
PMID:22022398 · one of two readings recorded this
number of axons in entorhinal cortex explants
increases
The total number of axons increased significantly in the presence of EGCG and GA in combination compared to control brain slices
PMID:22022398 · one of two readings recorded this
spinal cord inflammatory infiltrates (percentage of quadrants positive)
unclear
Upon quantification of the extent of inflammation, only the combined EGCG and GA treated group showed a statistically significant reduction in histopathology, compared to the control
PMID:22022398 · one of two readings recorded this
spinal cord inflammatory infiltrates (percentage of quadrants positive)
decreases, p = 0.05, n = 8
*p<0.05, n = 8 per group
PMID:22022398 · one of two readings recorded this
survival of HT22 cells after glutamate
no effect
Suboptimal doses of EGCG and GA showed little or no neuroprotective effect compared to control
PMID:22022398 · one of two readings recorded this
survival of HT22 cells after glutamate
increases
whereas the combination of 10 µg/ml EGCG and 50 µg/ml GA significantly increased survival of HT22 cells compared to controls
PMID:22022398 · one of two readings recorded this
survival of LN18 cells after TRAIL
no effect
Conversely, EGCG or GA alone did not induce a significant increase
PMID:22022398 · one of two readings recorded this
survival of LN18 cells after TRAIL
increases
Again, the combination of EGCG (10 µg/ml) and GA (12.5 µg/ml) showed a statistically significant increase in cell survival compared to control
PMID:22022398 · one of two readings recorded this
antigen-specific T-cell proliferation
decreases
inhibited antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response
PMID:22056360 · one of two readings recorded this
clinical symptoms and CNS pathology (leukocyte infiltration, demyelination) in myelin oligodendrocyte glycoprotein 35-55 induced experimental autoimmune encephalomyelitis in C57BL/6 mice
decreases, EGCG dose dependently attenuated clinical symptoms and pathological features
Not recorded as a finding: this platform holds no node for the endpoint
EGCG dose dependently attenuated clinical symptoms and pathological features (leukocyte infiltration and demyelination) in the central nervous system and inhibited antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response.
PMID:22056360 · one of two readings recorded this
clinical symptoms and pathological features (leukocyte infiltration, demyelination) of EAE
decreases
EGCG dose dependently attenuated clinical symptoms and pathological features (leukocyte infiltration and demyelination) in the central nervous system
PMID:22056360 · one of two readings recorded this
clinical symptoms of experimental autoimmune encephalomyelitis in C57BL/6 mice fed EGCG 0%, 0.15%, 0.3%, 0.6% in diet, with CNS leukocyte infiltration and demyelination, antigen-specific T-cell proliferation, cytokine production and CD4+ T-cell subsets
decreases
Not recorded as a finding: this platform holds no node for the endpoint
EGCG dose dependently attenuated clinical symptoms and pathological features (leukocyte infiltration and demyelination) in the central nervous system and inhibited antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response.
PMID:22056360 · one of two readings recorded this
delayed-type hypersensitivity skin response
decreases
inhibited antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response
PMID:22056360 · one of two readings recorded this
expression of transcription factors T-bet and RORγt
decreases
EGCG inhibited expression of transcription factors T-box expressed in T cells and retinoid-related orphan receptor-γt
PMID:22056360 · one of two readings recorded this
plasma intercellular adhesion molecule 1 and CCR6 expression in CD4(+) T cells
decreases
the plasma levels of intercellular adhesion molecule 1; and CCR6 expression in CD4(+) T cells
PMID:22056360 · one of two readings recorded this
production of interferon-γ, IL-17, IL-6, IL-1β and tumor necrosis factor-α
decreases
EGCG reduced production of interferon-γ, IL-17, IL-6, IL-1β, and tumor necrosis factor-α
PMID:22056360 · one of two readings recorded this
regulatory T-cell populations
increases
increased regulatory T-cell populations in lymph nodes, the spleen, and the central nervous system
PMID:22056360 · one of two readings recorded this
Th1 and Th17 cell populations
decreases
decreased types 1 and 17 helper T cells (Th1 and Th17, respectively)
PMID:22056360 · one of two readings recorded this
Triglycerides
no effect, n = 103
Intervention with PPE was not associated with significant changes in HDL-cholesterol or triglyceride levels
PMID:22246619 · one of two readings recorded this
IGF-1
no effect, n = 103
The three groups did not differ significantly in baseline concentrations of IGF-1 on in the change in this biomarker
PMID:22246619 · one of two readings recorded this
Baseline urinary epicatechin (EC)
unclear, p = 0.039
Although baseline EC levels were low, there were differences between the 3 groups (P=0.039)
PMID:22246619 · one of two readings recorded this
Change in all five urinary tea catechins
increases, n = 103
The differences in changes in all five catechins differed significantly between the placebo and the two PPE groups (Table 2)
PMID:22246619 · one of two readings recorded this
Change in body weight or BMI
no effect, n = 103
There were no significant differences in changes in body weight or BMI after 2 months of intervention between the placebo and PPE groups
PMID:22246619 · one of two readings recorded this
Change in liver enzymes (ALP, AST, ALT)
no effect, n = 103
The placebo and PPE groups did not differ significantly in differences in changes in these three liver enzymes (Table 1)
PMID:22246619 · one of two readings recorded this
fasting serum glucose, insulin, LDL-cholesterol, total cholesterol, HDL, triglycerides, HbA1c and sex hormones after 2 months
decreases, change in glucose differed between placebo and the two PPE groups combined, p = 0.008, n = 103
Not recorded as a finding: the intervention held more than the compound
The difference in change in glucose concentrations between the placebo and the two PPE groups was statistically significant (P=0.008).
PMID:22246619 · one of two readings recorded this
Glucose, difference in change placebo vs two PPE groups
decreases, p = 0.008, n = 103
The difference in change in glucose concentrations between the placebo and the two PPE groups was statistically significant (P=0.008)
PMID:22246619 · one of two readings recorded this
Sources cited
14 papers
- Subject
- (-)-epigallocatechin 3-gallate
- Findings
- 20
- Papers
- 14
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.record2025PMID:410060341 finding
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2025PMID:408856033 findings
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.record2020PMID:330500291 finding
Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.record2020PMID:320929512 findings
The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats.record2020PMID:327296621 finding
Green Tea Polyphenol (-)-Epigallocatechin Gallate (EGCG) Attenuates Neuroinflammation in Palmitic Acid-Stimulated BV-2 Microglia and High-Fat Diet-Induced Obese Mice.record2019PMID:316149511 finding
Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.record2018PMID:299165502 findings
Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.record2018PMID:294803241 finding
Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans.record2016PMID:273245901 finding
Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet.record2015PMID:265364643 findings
Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.record2013PMID:235380071 finding
(-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice.record2011PMID:217795551 finding
(-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer.record2011PMID:216335971 finding
Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans.record2010PMID:199528441 finding
Other names
18 names
Resolves to: (-)-epigallocatechin 3-gallate
- Also called
- (-)-epigallocatechin 3-O-gallate(-)-epigallocatechin gallate(-)-epigallocatechin-3-O-gallate(-)-epigallocatechol gallate(−)-epigallocatechin 3-O-gallate(−)-epigallocatechin gallate(−)-epigallocatechin-3-O-gallate(−)-epigallocatechol gallate[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate3-O-galloyl-(-)-epigallocatechin3-O-galloyl-(−)-epigallocatechinEGCGepigallocatechin 3-gallateepigallocatechin 3-O-gallateepigallocatechin gallateL-epigallocatechin gallateNVP-XAA 723
- Systematic name
- (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate